Protego Biopharma Secures $130 Million in Series B Financing
Protego Biopharma, Inc. has successfully completed an oversubscribed Series B financing round, raising an impressive $130 million. This milestone funding round showcases the faith held by prominent investors in the company's innovative approach to tackle systemic amyloid diseases.
Strong Backing from Leading Investors
The financing was led by Novartis Venture Fund and Forbion, with new funding contributions from Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures. Additionally, Protego received renewed support from existing investors like Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research. Their continued investment highlights a strong conviction in Protego’s methodology and its potential impact on patient care.
Investor Trust and Company Leadership
Under the guidance of Ed Hurwitz, Executive Chairman, and Chris Weyrer, M.D., Ph.D., Principal at Vida Ventures, Protego is poised to advance its lead program. This is critical as these leaders bring a wealth of experience and strategic insight to the table, facilitating a robust path for the company's future endeavors.
Funding Purpose and Clinical Advancements
The funds raised will be directed towards advancing PROT-001, Protego's lead candidate into a pivotal clinical trial for AL amyloidosis. This rare and often severe condition emerges from protein misfolding, leading to significant organ damage, particularly affecting the heart. The focus on this area reflects an urgent need for innovative solutions and effective treatments.
A Message from the CEO
Brent Warner, the Chief Executive Officer of Protego Biopharma, expressed immense gratitude for the unwavering support from existing investors. "With the capital raised, we are positioned to advance PROT-001 into pivotal trials, moving closer to delivering the first disease-modifying therapy for AL amyloidosis and offering new hope to patients who currently face devastating outcomes," stated Warner. His leadership aims to transform lives through the science and urgency of their mission.
Innovative Therapeutic Strategies
Protego’s strategy is grounded in human genetics, employing a unique pharmacological chaperone mechanism. This innovative approach utilizes small molecules as cellular guides to ensure proteins fold correctly, effectively addressing the root cause of diseases rather than just managing symptoms. By stabilizing immunoglobulin light chains and preventing amyloid accumulation, PROT-001 aims to alter the trajectory of not just AL amyloidosis but various protein misfolding disorders that historically have had limited treatment options.
Industry Recognition and Potential Impact
Tim Lohoff, PhD, Principal at Forbion, highlighted Protego's distinctive approach, emphasizing its potential to revolutionize treatment for patients suffering from AL amyloidosis. "Protego exemplifies our commitment to investing in bold teams that turn groundbreaking science into meaningful medical and commercial impact," he noted, reflecting the company's place within the biotech landscape.
About Protego Biopharma
Founded in San Diego, Protego Biopharma is dedicated to developing innovative small-molecule drugs that target pathways associated with protein misfolding. The company’s vision is to reprogram cellular processes to restore proper protein function, aiming to provide targeted therapies for rare and systemic diseases, ultimately enhancing patient outcomes.
Frequently Asked Questions
What is Protego Biopharma?
Protego Biopharma is a biotechnology company focused on developing small-molecule therapeutics aimed at addressing systemic amyloid diseases and other protein misfolding disorders.
What is the significance of the $130 million funding?
The significant funding will help accelerate the clinical development of PROT-001, their lead candidate targeting AL amyloidosis, into pivotal trials.
Who are the key investors in this funding round?
Key investors include Novartis Venture Fund, Forbion, Omega Funds, Droia Ventures, and YK Bioventures among others.
What does PROT-001 aim to achieve?
PROT-001 aims to provide a disease-modifying therapy for AL amyloidosis by targeting the root cause of the disease through innovative mechanisms.
Where is Protego Biopharma located?
Protego Biopharma is based in San Diego, California, and aims to develop advanced therapies that improve patient outcomes and replace conventional treatments.
